Updated: 02/2025
PARP Approved: 03/2025

Prior Authorization Criteria

Filspari (sparsentan)

All requests for Filspari (sparsentan) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Coverage may be provided with a diagnosis of **primary immunoglobulin A nephropathy (IgAN)** and the following criteria is met:

- Must be prescribed by or in consultation with a nephrologist
- Diagnosis has been confirmed by biopsy
- Must have an estimated glomerular filtration rate ≥ 30 ml/min/1.73m2
- Must have a total urine protein ≥ 1.0 g/day
- Must be at risk of rapid disease progression defined as having a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g
- Must be on a stable and maximum tolerated dose of a renin-angiotensin system (RAS) inhibitor treatment [i.e. angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB)] for at least 3 months or had an intolerance or contraindication to RAS inhibitor treatment.
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Must be age-appropriate according to FDA-approved labeling, nationally recognized compendia, or evidence-based practice guidelines
- **Initial Duration of Approval:** 6 months
- **Reauthorization criteria**
    - Decrease from baseline in total urine protein or UPCR
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.

HIGHMARK WHOLECARE

Updated: 02/2025
PARP Approved: 03/2025

FILSPARI (SPARSENTAN) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Wholecare Pharmacy Services. **FAX:** (888) 245-2049
If needed, you may call to speak to a Pharmacy Services Representative. **PHONE**: (800) 392-1147 Mon – Fri 8:30am to 5:00pm

PROVIDER INFORMATION

Requesting Provider:	Provider NPI:
Provider Specialty:	Office Contact:
State license #:	Office NPI:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:	
Member ID:	Member weight:	Height:

REQUESTED DRUG INFORMATION

Medication:	Strength:	
Directions:	Quantity:	Refills:
Is the member currently receiving requested medication? ☐ Yes ☐ No	Date Medication Initiated:	

Billing Information

This medication will be billed: ☐ at a pharmacy **OR** ☐ medically, JCODE:_____

Place of Service: ☐ Hospital ☐ Provider's office ☐ Member's home ☐ Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Diagnosis:	ICD Code:

Has the diagnosis been confirmed by biopsy? ☐ Yes ☐ No

What is the estimated glomerular filtration rate? _____
What is the total urine protein? _____
What is the urine protein-to-creatinine ration (UPCR)? _____

Is the member currently stable on renin-angiotensin system (RAS) inhibitor treatment (ie. ACE or ARB) ☐ Yes, please list below
☐ No

CURRENT or PREVIOUS THERAPY

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

REAUTHORIZATION

Has the member experienced an improvement with treatment? ☐ Yes ☐ No

Which of the following have improved and what is the current level?
- ☐ Total urine protein _____
- ☐ Urine protein-to-creatinine ration (UPCR)? _____

SUPPORTING INFORMATION or CLINICAL RATIONALE

Prescribing Provider Signature	Date